Table 1.
Demographic data and follow-up duration for cohorts examined.
| Cohort | Size (n) | Median age at baseline, yrs (IQR) | Median age at last follow-up, yrs (IQR) | Total follow-up, women years at risk (median) | BRCA pathogenic variant status (%) | Prior history of breast cancer (%) | Prior history of tamoxifen use (%) |
|---|---|---|---|---|---|---|---|
| Retrospective cohort (1/1/1980–31/12/17) | 2609 | 20.0 (20.0–31.6) | 48.8 (40.5–57.9) | 59199 (23.8) |
BRCA1 1350 (51.7%) BRCA2 1259 (48.3%) |
Yes 1259 (48.2%) No 1350 (51.7%) |
Yes 311 (11.9%) No 557 (21.3%) Unknown 1741 (66.6%) |
| Date of family pathogenic variant report | 1811 | 44.1 (34.9–54.6) | 49.1 (40.2–59.1) | 9412 (3.5) |
BRCA1 906 (50.0%) BRCA2 905 (50.0%) |
Yes 907 (50.1%) No 901 (49.8%) Unknown 3 (0.2%) |
Yes 260 (14.4%) No 490 (27.1%) Unknown 1061 (58.6%) |
| Date of personal pathogenic variant report | 1617 | 45.1 (37.0–55.1) | 49.2 (40.9–58.8) | 6375 (2.4) |
BRCA1 817 (50.5%) BRCA2 800 (49.5%) |
Yes 847 (52.4%) No 768 (47.5%) Unknown 2 (0.1%) |
Yes 258 (16.0%) No 478 (29.6%) Unknown 881 (54.4.%) |
| Date of RRSO | 546 | 45.8 (40.4–52.6) | 51.3 (45.4–58.9) | 2865 (2.9) |
BRCA1 274 (50.2%) BRCA2 272 (49.8%) |
Yes 283 (51.8%) No 263 (48.2%) |
Yes 103 (18.9%) No 178 (32.6%) Unknown 265 (48.5%) |
IQR, interquartile range.